Source:http://linkedlifedata.com/resource/pubmed/id/20817013
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
45
|
| pubmed:dateCreated |
2010-10-12
|
| pubmed:databankReference | |
| pubmed:abstractText |
We conducted a multi-center, randomized, laboratory-blinded clinical trial in 185 healthy adults (<60 years) and 107 elders (>60 years) to examine the immunogenicity and safety of different doses of an inactivated, monovalent, non-adjuvanted, split vaccine against the 2009 pandemic influenza A (H1N1) virus. The 186 adults were assigned to three treatment groups, i.e., one 15 ?g hemagglutination (HA) antigen dose, two 15 ?g or 30 ?g HA doses in 3 weeks apart, and the 107 elders were treated with two 15 ?g or 30 ?g doses in 3 weeks apart. Prior to the vaccination, 4.8% subjects had hemagglutination-inhibition (HAI) antibody titers of 1:40 or more. By day 21 post-vaccination of one dose of 15 ?g HA, the seroprotective rate was 95.1% and 75.5% in subjects <60 and >65 years of age, respectively; by day 21 post the second 15 ?g HA dose, the seroprotective rates were 93.2% and 73.1%, respectively. The seroprotective rates for recipients of 30 ?g HA antigen by day 21 were 95.2% for subjects <60 years and 81.1% for subjects >65 years of age, that was boosted to 98.3% and 80.4%, respectively with a second dose of 30 ?g HA antigen. No vaccine-related serious adverse events occurred. The data indicated a single 15 ?g HA dose of the vaccine induced a protective immune response in most adults, including the elders >60 years of age, and a booster dose at the third week did not render a higher level of antibody response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1873-2518
|
| pubmed:author |
pubmed-author:ChangFeng-YeeFY,
pubmed-author:ChenChien-HuiCH,
pubmed-author:ChenChin-ICI,
pubmed-author:HsiehSzu-MinSM,
pubmed-author:HuangKuo-ChinKC,
pubmed-author:HuangLi-MinLM,
pubmed-author:KaoTsui-MaiTM,
pubmed-author:KungHsiang-ChiHC,
pubmed-author:LeeWen-SenWS,
pubmed-author:LeeYi-ChienYC,
pubmed-author:LiuHsing-JinHJ,
pubmed-author:LiuYung-ChingYC,
pubmed-author:WangNing-ChiNC
|
| pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
21
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
7337-43
|
| pubmed:meshHeading |
pubmed-meshheading:20817013-Adult,
pubmed-meshheading:20817013-Aged,
pubmed-meshheading:20817013-Aged, 80 and over,
pubmed-meshheading:20817013-Antibodies, Viral,
pubmed-meshheading:20817013-Antibody Formation,
pubmed-meshheading:20817013-Epidemics,
pubmed-meshheading:20817013-Female,
pubmed-meshheading:20817013-Hemagglutination Inhibition Tests,
pubmed-meshheading:20817013-Hemagglutinin Glycoproteins, Influenza Virus,
pubmed-meshheading:20817013-Humans,
pubmed-meshheading:20817013-Influenza, Human,
pubmed-meshheading:20817013-Influenza A Virus, H1N1 Subtype,
pubmed-meshheading:20817013-Influenza Vaccines,
pubmed-meshheading:20817013-Male,
pubmed-meshheading:20817013-Middle Aged,
pubmed-meshheading:20817013-Taiwan,
pubmed-meshheading:20817013-Vaccination,
pubmed-meshheading:20817013-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
|
| pubmed:affiliation |
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|